<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725504</url>
  </required_header>
  <id_info>
    <org_study_id>SU-07072008-1232</org_study_id>
    <nct_id>NCT00725504</nct_id>
  </id_info>
  <brief_title>Effect of IV Lidocaine Infusions on Pain</brief_title>
  <official_title>Effect of IV Lidocaine Infusions on Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Our goals for this study involve using intravenous lidocaine as it is normally used in the
      Stanford Pain Management Center to assess the effect of intravenous lidocaine on chronic
      pain. Studies have been done determining the efficacy of intravenous lidocaine for treating
      pain but little research has been done to determine the effects of an intravenous lidocaine
      infusion on the different components of the pain experience. Our study will incorporate pain
      quality measures both before and during the infusions of lidocaine to determine changes in
      present pain intensity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient will receive an intravenous infusion of lidocaine. Drug will be infused using a
      computer-controlled paradigm. This paradigm allows increasing plasma concentrations in a
      step-wise manner, keeping the concentration during each infusion step constant. Plasma
      concentrations will be increased gradually from 0 to 5 ug/ml in a method at the discretion of
      the medical team. This will be conducted according to standard medical practice for the
      infusion and the study procedures will not affect the infusion paradigm. Total infusion time
      is approximately 1-2 hours. During the course of the study, the primary outcome measure was
      changed from blood oxygenation level dependent (BOLD) signal to pain intensity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Present Pain Intensity</measure>
    <time_frame>Patients completed the VAS of present pain intensity at each infusion level. Each infusion level took approximately one hour, and the assessment was done at the end of the hour (approximately 3 hours total).</time_frame>
    <description>Present pain intensity was measured using the visual analog scale (VAS). This is scored between 0 (no pain) to 10 (worst possible pain).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Lidocaine infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will receive an intravenous infusion of lidocaine. Plasma concentrations will be increased gradually from 0-5 µg/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous lidocaine</intervention_name>
    <description>Intravenous lidocaine administered up to 5 µg/ml.</description>
    <arm_group_label>Lidocaine infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:- subjects between the ages of 18 and 100 years for clinical component;
        subjects between the ages of 18 and 70 for the MRI component

          -  meets the study criteria of chronic pain of either peripheral or central origin

          -  male or a non-pregnant, non-lactating female. If females are of reproductive potential
             (i.e., not surgically sterilized and/or not post menopausal), they must be practicing
             an accepted method of birth control, agree to a urine pregnancy test at the start of
             each study session (for patient scheduled through the clinic, this has already been
             addressed by the recommending physician)

          -  is not currently on a sodium channel blocking agent, anticonvulsant, or tricyclic
             antidepressant,

          -  must be able to comply with any other study requirements and complete experimental
             tasks

          -  have no reported substance abuse within the past six months;

        Exclusion Criteria:- subject is lactating or pregnant;

          -  subject suffers from clinically significant cardiac, pulmonary, renal or liver
             disease;

          -  subject allergic to lidocaine.

          -  MRI Component: any metal objects (especially surgical clips), devices, or implants or
             any other MRI contraindication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Mackey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2008</study_first_posted>
  <results_first_submitted>March 4, 2017</results_first_submitted>
  <results_first_submitted_qc>March 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2017</results_first_posted>
  <last_update_submitted>March 4, 2017</last_update_submitted>
  <last_update_submitted_qc>March 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sean Mackey</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>71 patients were recruited through the Stanford University Pain Management Center.</recruitment_details>
      <pre_assignment_details>Individuals were assessed for neuropathic pain prior to enrollment. Those with co-morbid cardiac disease were excluded from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lidocaine Infusion</title>
          <description>Each participant will receive an intravenous infusion of lidocaine. Plasma concentrations will be increased gradually from 0-5 ug/ml.
Intravenous lidocaine: Intravenous lidocaine administered during fMRI scan at a maximum dose of 3mcg/ml</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Seventy-one patients with chronic neuropathic pain</population>
      <group_list>
        <group group_id="B1">
          <title>Lidocaine Infusion</title>
          <description>Each participant will receive an intravenous infusion of lidocaine. Plasma concentrations will be increased gradually from 0-5 ug/ml.
Intravenous lidocaine: Intravenous lidocaine administered during fMRI scan at a maximum dose of 3mcg/ml</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" lower_limit="17" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Present Pain Intensity</title>
        <description>Present pain intensity was measured using the visual analog scale (VAS). This is scored between 0 (no pain) to 10 (worst possible pain).</description>
        <time_frame>Patients completed the VAS of present pain intensity at each infusion level. Each infusion level took approximately one hour, and the assessment was done at the end of the hour (approximately 3 hours total).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Each participant was tested at the zero infusion rate.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Each participant received a placebo-saline infusion.</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine 3 µg/ml</title>
            <description>Each participant received an intravenous infusion of 3 µg/ml of lidocaine.</description>
          </group>
          <group group_id="O4">
            <title>Lidocaine 5 µg/ml</title>
            <description>Each participant received an intravenous infusion of 5 µg/ml of lidocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Present Pain Intensity</title>
          <description>Present pain intensity was measured using the visual analog scale (VAS). This is scored between 0 (no pain) to 10 (worst possible pain).</description>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" spread="0.23"/>
                    <measurement group_id="O2" value="5.64" spread="0.24"/>
                    <measurement group_id="O3" value="4.92" spread="0.27"/>
                    <measurement group_id="O4" value="4.18" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected during the infusion period (approximately one hour) for each participant.</time_frame>
      <desc>The definitions for adverse event and serious adverse event did not differ from clinicaltrials.gov.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lidocaine Infusion</title>
          <description>Each participant will receive an intravenous infusion of lidocaine. Plasma concentrations will be increased gradually from 0-5 µg/ml.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Transient central nervous system side effects</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sean Mackey, Chief, Division of Pain Medicine, Director, Stanford Systems Neuroscience and Pain Lab</name_or_title>
      <organization>Stanford University</organization>
      <phone>(650) 498-6477</phone>
      <email>smackey@pain.stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

